{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:47:24Z","timestamp":1771462044158,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T00:00:00Z","timestamp":1536883200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10067-018-4294-9","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T00:52:29Z","timestamp":1536886349000},"page":"585-590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Mycophenolate mofetil treatment with or without a calcineurin inhibitor in resistant inflammatory myopathy"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5172-1102","authenticated-orcid":false,"given":"Hironari","family":"Hanaoka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harunobu","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomofumi","family":"Kiyokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Takakuwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimito","family":"Kawahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,14]]},"reference":[{"key":"4294_CR1","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMra1402225","volume":"372","author":"MC Dalakas","year":"2015","unstructured":"Dalakas MC (2015) Inflammatory muscle diseases. N Engl J Med 372:1734\u20131747","journal-title":"N Engl J Med"},{"key":"4294_CR2","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1586\/1744666X.2015.1082908","volume":"11","author":"S Moghadam-Kia","year":"2015","unstructured":"Moghadam-Kia S, Aggarwal R, Oddis CV (2015) Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert Rev Clin Immunol 11:1265\u20131275","journal-title":"Expert Rev Clin Immunol"},{"key":"4294_CR3","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sanchez-Guerrero J, Solomons N, Wofsy D, the Aspreva Lupus Management Study Group (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103\u20131112","journal-title":"J Am Soc Nephrol"},{"key":"4294_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7326\/M14-1030","volume":"162","author":"Z Liu","year":"2015","unstructured":"Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, Chen J, Lin H, Liu F, He Y, He Y, Miao L, Chen N, Li Y, Gu Y, Shi W, Hu W, Liu Z, Bao H, Zeng C, Zhou M (2015) Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 162:18\u201326","journal-title":"Ann Intern Med"},{"key":"4294_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3899\/jrheum.121043","volume":"40","author":"A Fischer","year":"2013","unstructured":"Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER et al (2013) Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40:640\u2013646","journal-title":"J Rheumatol"},{"key":"4294_CR6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/rheumatology\/kel336","volume":"46","author":"CN Pisoni","year":"2007","unstructured":"Pisoni CN, Cuadrado MJ, Khamashta MA, Hughes GR, D\u2019Cruz DP (2007) Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 46:516\u2013518","journal-title":"Rheumatology (Oxford)"},{"key":"4294_CR7","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/01.wnl.0000208416.32471.c0","volume":"66","author":"J Rowin","year":"2006","unstructured":"Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN (2006) Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 66:1245\u20131247","journal-title":"Neurology"},{"key":"4294_CR8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/rheumatology\/keh499","volume":"44","author":"V Majithia","year":"2005","unstructured":"Majithia V, Harisdangkul V (2005) Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 44:386\u2013389","journal-title":"Rheumatology (Oxford)"},{"key":"4294_CR9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/mus.10026","volume":"25","author":"C Schneider","year":"2002","unstructured":"Schneider C, Gold R, Sch\u00e4fers M, Toyka KV (2002) Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 25:286\u2013288","journal-title":"Muscle Nerve"},{"key":"4294_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.autrev.2009.04.003","volume":"9","author":"MG Danieli","year":"2009","unstructured":"Danieli MG, Calcabrini L, Calabrese V, Marchetti A, Logullo F, Gabrielli A (2009) Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev 9:124\u2013127","journal-title":"Autoimmun Rev"},{"key":"4294_CR11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. N Engl J Med 292:344\u2013347","journal-title":"N Engl J Med"},{"key":"4294_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/rheumatology\/ken441","volume":"48","author":"MO Harris-Love","year":"2009","unstructured":"Harris-Love MO, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, Cintas HL, McGarvey CL, James-Newton L, Pokrovnichka A, Moini B, Cabalar I, Lovell DJ, Wesley R, Plotz PH, Miller FW, Hicks JE, Rider LG (2009) Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology (Oxford) 48:134\u2013139","journal-title":"Rheumatology (Oxford)"},{"key":"4294_CR13","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.3899\/jrheum.141182","volume":"42","author":"D Khanna","year":"2015","unstructured":"Khanna D, Mittoo S, Aggarwal R, Proudman SM, Dalbeth N, Matteson EL, Brown K, Flaherty K, Wells AU, Seibold JR, Strand V (2015) Connective tissue disease-associated interstitial lung diseases (CTD-ILD) - report from OMERACT CTD-ILD Working Group. J Rheumatol 42:2168\u20132171","journal-title":"J Rheumatol"},{"key":"4294_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","volume":"46","author":"Y Yamasaki","year":"2007","unstructured":"Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S, Kurihara Y, Osada H, Satoh M, Ozaki S (2007) Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/ dermatomyositis. Rheumatology (Oxford) 46:124\u2013130","journal-title":"Rheumatology (Oxford)"},{"key":"4294_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","volume":"94","author":"MM Joffe","year":"1993","unstructured":"Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, Plotz PH, Miller FW (1993) Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 94:379\u2013387","journal-title":"Am J Med"},{"key":"4294_CR16","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/S0140-6736(99)01927-3","volume":"353","author":"CV Oddis","year":"1999","unstructured":"Oddis CV, Sciurba FC, Elmagd KA, Starzl TE (1999) Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 353:1762\u20131763","journal-title":"Lancet"},{"key":"4294_CR17","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/art.22521","volume":"56","author":"T Sugihara","year":"2007","unstructured":"Sugihara T, Sekine C, Nakae T, Khyama K, Harigai M, Iwakura Y et al (2007) A new murine model to define the critical pathologyc and therapeutic mediators of polymyositis. Arthritis Rheum 56:1304\u20131314","journal-title":"Arthritis Rheum"},{"key":"4294_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1525-1470.2011.01501.x","volume":"28","author":"YE Chiu","year":"2011","unstructured":"Chiu YE, Co DO (2011) Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use. Pediatr Dermatol 28:357\u2013367","journal-title":"Pediatr Dermatol"},{"key":"4294_CR19","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE, and the RIM Study Group (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthtitis Rheum 65:314\u2013324","journal-title":"Arthtitis Rheum"},{"key":"4294_CR20","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/art.40064","volume":"69","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM et al (2017) International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation. 2016 American College of Rheumatology\/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol 69:898\u2013910","journal-title":"Arthritis Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4294-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4294-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4294-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T19:18:12Z","timestamp":1568402292000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4294-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,14]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["4294"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4294-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,14]]},"assertion":[{"value":"3 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of St. Marianna University School of Medicine (approval number 3502). Since this study was conducted under a retrospective cohort design without any samples taken besides those for clinical use, written informed consent was not required, in accordance with the guidelines of the Ministry of Health, Labour, and Welfare of Japan.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}